Home > Insider Trading > Filing (0001133416-23-000041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1133416	Galectin Therapeutics Inc	GALT	Pharmaceutical Preparations (2834)	043562325

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1725595	Joel Lewis	C/O Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd., Ste 240 Norcross GA 30071	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-02-16	1,000	$1.52	1,000	No	4	P	Indirect	as UTMA custodian for a minor child

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	as UTMA custodian for a minor child

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	886,520	Direct

Footnotes

Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024.
Represents shares underlying DSUs and Common Stock.
These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.